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Background/introduction
Osteoid osteoma (OO) is a relatively common benign
bone tumor (2-3% of all bone tumors, 10% of benign
bone tumors) usually developing in children and young
adults. It is quite painful and patients typically complain
of localized pain that is worse at night and characteristi-
cally relieved by non-steroid anti-inflammatory drugs
(NSAIDs). Conventional treatment options include sur-
gery, systemic drugs administration, and imaging guided
percutaneous procedures. Minimally invasive procedures
are considered of primary importance, and this is even
enhanced considering the benign nature of the lesion
and the young age of the affected population. CT guided
radiofrequency ablation (CTgRFA) is the most popular
percutaneous technique with clinical success rate
reported between 85% and 98%. However, CTgRFA is
still rather invasive, and it requires CT-guidance, with
obvious concerns linked to radiosensitivity especially of
young patients. MR guided focused ultrasound surgery
(MRgFUS) is a minimally invasive procedure that can be
performed relatively fast, in a single session and with
limited amount of energy deposition and no use of
ionizing radiation.
Methods
From March 2013 to May 2014, 7 consecutive patients
(6M, 1F; mean age 33.5±12.4, range 19-64 years old) with
superficial osteoid osteomas of the lower limb were trea-
ted at our Institute with MRgFUS (ExAblate 2100,
InSightec). Six lesions were located at the femur, one at
the tibia. The mean time between the onset of symptoms
and the diagnosis was 3.75 months (range 1-9 months).
One patient had previously undergone CTgRFA (in a
different hospital) but experienced a relapse of symptoms
4 months after, and imaging revealed that the lesion was
still there. For all other patients MRgFUS was used as
first-line treatment (apart from NSAIDs). Patients were
examined clinically (visual analogue scale score – VAS;
Qol) at baseline and at 1, 3, 6 and 12 months of follow-up.
Results and conclusions
In five patient the 12-month follow-up period has been
completed, while two patients are still at 1- and 3-month
check points. The mean VAS at the baseline was 7.5. In all
patients VAS dropped to 0 after 1 month. In 6 patients
(86%) VAS remained 0 during the follow-up, while in
1 patient VAS dropped from 9 to 0 after 1 month but rose
to 2 after 3 months (6-month control available, no recur-
rence documented). No intra-operative complications or
short/mid-terms adverse events were observed.
These preliminary data showed that MRgFUS can be
effectively adopted for the treatment of superficial OO
and can be performed safely and with a high rate of suc-
cess for the noninvasive treatment of this condition.
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